Track the Good Works II Acquisition Corp. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Industrials sector, Good Works II Acquisition Corp. has published 9 public disclosures. The latest transaction was disclosed on 12 July 2022 (Don). Among the most active insiders: GROSSMAN CARY M. The full history is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
9 of 9 declarations
Good Works II Acquisition Corp. is a U.S.-listed special purpose acquisition company (SPAC) traded on the NASDAQ in the United States. As a SPAC, it is not a conventional operating business with product sales or recurring industrial revenue; rather, it was created as a public acquisition vehicle to complete a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more private companies. The company was incorporated in Delaware on July 27, 2020, placing it squarely in the wave of SPAC formations designed to provide an expedited route to the public markets for growth-stage businesses. In practical terms, the investment case is driven less by historical operating performance and more by the attractiveness of the eventual target, market conditions, and transaction execution. Good Works II’s SEC filings show the company was organized to identify an appealing business with growth potential, capital needs, or a strategic rationale for becoming publicly listed. In October 2022, the company announced a definitive business combination agreement with Direct Biologics, a late-stage biotechnology company, indicating a potential life sciences orientation; however, investors should confirm the current status of that transaction in the most recent SEC filings before drawing firm conclusions. Because this is a SPAC, it should be analyzed as a transaction platform rather than a normal operating company. That means the key risks are deal completion risk, timing risk, dilution, redemption pressure, and the possibility that the target business changes over time. From a competitive standpoint, Good Works II competes indirectly with other SPACs and acquisition vehicles for access to attractive private companies, especially in markets where financing conditions are tighter and public-market valuations are volatile. Recent headline risk and news flow have therefore centered on corporate actions and SEC disclosures, including insider transaction reporting such as Form 4 filings, rather than on commercial KPIs like revenue growth or margins. For French-speaking investors, the main takeaway is that Good Works II Acquisition Corp. on the NASDAQ in the United States represents a high-risk, event-driven equity story: limited standalone operations, high dependence on capital markets, and upside only if the company completes a value-accretive business combination with the right target under favorable terms.